Wellnex Life Ltd · ASX:WNX
Wellnex Life — Investor Presentation (August 2024)
22 slides from Wellnex Life's investor presentation, Aug 19, 2024
Slide 1: Next Generation Consumer Health Products
For personal use only Next Generation Consumer Health Products Wellnex Life Limited ASX: WNX August 2024
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE STRICTLY CONFIDENTIAL AND (SAVE AS SET OUT BELOW) ARE NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, A
Slide 3: Important Notice & Disclaimer
Important Notice & Disclaimer Strand and Orana are authorised and regulated in the United Kingdom by the FCA and are acting exclusively for the Company and for no one else in connection with the Admission and will not regard any other person (whether or not a recipient of the Materials) as a client
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer Solely for the purposes of the product governance requirements of Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the UK Product Governance Requirements), and disclaiming all and any liability, whether arising in tort, contract or o
Slide 5: Team: Decades of Experience in Healthcare & FMCG
Wellnex Life Team Decades of Experience in Healthcare & FMCG Zack Bozinovski George Karafotias For personal use only Managing Director Chief Executive Officer • Over 35 years of senior experience within FMCG and • Specialist in restructuring, reinventing and implementing Pharmaceutical companies in
Slide 6: Non-Executive Directors
Wellnex Life Non-Executive Directors Diverse Skills Matrix to Deliver Guidance on Behalf of Stakeholders Andrew Vidler – Non-Executive Director • Over 30 years experience across retail, consumer health products and retail pharmacy. For personal use only • Currently Pacific Smiles Group’s (PSQ:ASX) M
Slide 7: Investment Highlights
Investment Highlights WNX is an ASX-listed consumer health company with a diversified portfolio of unique products, brands, and IP licensed to global blue-chip customers. For personal use only Transformational Initiation of Global Chemist Warehouse Expansion of Haleon Margins & Distribution of JV in
Slide 8: Asset Portfolio
Wellnex Life Asset Portfolio For personal use only Licensing Contracts Owned Brands Joint Ventures 8
Slide 9: Transformation of Wellnex Life
Transformation of Wellnex Life JULY 2021 AUG 2021 OCT 2021 APRIL 2022 DEC 2022 JAN 2023 For personal use only Increased Range of Wakey Strategy Refresh JV with Chemist Warehouse Wakey Wakey & The Iron IP License agreement Acquisition of Wakey and Launch of for Wagner Liquigesic Company Launched for
Slide 10: Profitability Evolution
Wellnex Life Profitability Evolution Successful transition from low-margin brokerage to high-margin brand sales For personal use only Jan - June 2023 Jan - June 2024 $4.4m $4,500,000 Contract Brands 16% Brokerage 0% Manufacturing 16% $4,000,000 $3,500,000 $2.7m $3,000,000 $2,500,000 $2,000,000 $1,50
Slide 11: Brand Growth & Expanding Margins
Brand Growth & Expanding Margins WNX’s portfolio of 100% owned brands are high gross margin products that are growing Company profitability rapidly. A$14.0m 40.0% • First WNX brands launched in FY22. For personal use only 35.0% A$12.0m • Approx. 126% CAGR revenue growth between FY22 and FY24 A$10.0m
Slide 12: Global Expansion of Licensing Deal
Global Expansion of Licensing Deal Growing our Contract Manufacturing revenue through global expansion with Haleon • First dossier approved in FY22 followed A$9.0m by first major contract with Arrotex. For personal use only A$8.0m • TGA changes to paracetamol pack sizes A$7.0m disrupted revenues in
Slide 13: Wellness Life Medicinal Cannabis
Wellness Life Medicinal Cannabis A joint venture between Chemist Warehouse, OneLife Botanicals, & Wellnex Life For personal use only Supplier Target ~50% Avg. Gross Margin Cultivator & Manufacturer JV Brand 45% Patient Authorised Prescriber 45% 10% 13
Slide 14: Australian Medicinal Cannabis Market Growth
Australian Medicinal Cannabis Market Growth Huge Opportunity in an Emerging Alternative Medicine Market A$800m 120.0k A$700m • In 2016, the Australian Government legalised 100.0k access to medicinal cannabis. For personal use only A$600m • Since legalisation, the market has grown at an 80.0k approxi
Slide 15: FY25 Domestic Growth Strategy
Wellnex Life FY25 Domestic Growth Strategy Brand building organic growth and opportunistic acquisitions Acquisitions Licensing Targeted buyouts of high Fortifying relationship margin brands leveraged with Haleon and Arrotex For personal use only to WNX distribution network Joint Ventures Organic Wel
Slide 16: International Growth Strategy
Wellnex Life International Growth Strategy Leveraging domestic success into an international growth strategy Pain Away is Australia’s largest natural topical For personal use only pain relief product. Wellnex Life are seizing on an opportunity to export the brand globally. First international sales
Slide 17: UK Dual Listing
Wellnex Life UK Dual Listing Benefits of listing on the London Stock Exchange & Selected European Public Comparables 1 Underpins European Expansion 2 Deeper Capital Pool 3 Higher Valuation Trading Multiples 4 Greater Stock Liquidity For personal use only LTM NTM LTM NTM 22.5x 5.2x 4.4x 18.1x 16.5x 1
Slide 18: Corporate Structure
Wellnex Life Corporate Structure Trading on the ASX under the ticker WNX Capital Structure WNX Shares on Issue 1,401,882,652 For personal use only WNX Options on Issue1 333,276,394 Fully Diluted Shares on Issue 1,735,159,046 Fully Diluted Equity Value2 $39,908,658 1. Options issued at various strike
Slide 19: Thank You
For personal use only Thank You FOR FURTHER INFORMATION CONTACT THE FOLLOWING: George Karafotias Chief Executive Officer Wellnex Life Limited ABN 77 150 759 363 george.k@wellnexlife.com.au Suite 68, Building 2, Level 3, 574 Plummer Street, Port Zack Bozinovski Melbourne VIC 3207, Australia Managing
Slide 20: Appendix
For personal use only Appendix
Slide 21: 100% Owned Brands
Wellnex Life 100% Owned Brands Innovative and Unique Market Leading Brands For personal use only Pain Away Wakey Wakey Nighty Night The Iron Company Mr. Bright Australia’s second largest1 Australia’s first Complimentary Australia’s first Complimentary Australia’s first Unique natural teeth topical p
Slide 22: Intellectual Property
Wellnex Life Intellectual Property Formulating and Launching TGA Complimentary and Registered Medicines Pharmaceutical Dossier Product Development For personal use only • A comprehensive set of documents submitted to • Strong R&D spend over FY22 & FY23 the Therapeutics Goods Administration (TGA) • I